Cannabigerol
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Cannabigerol (CBG) is a naturally-occurring cannabinoid of the terpenophenol class. It is the biosynthetic precursor to THC, CBD, and all major phytocannabinoids — earning it the designation "the mother of cannabinoids." CBG is a weak partial agonist at CB1 and CB2 receptors,[1][2] producing its effects primarily through TRP channel modulation, anandamide reuptake inhibitor,[3] and predicted 5-HT₁A partial agonism.[4]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First isolated from hashish by Gaoni and Mechoulam in 1964, CBG was among the earliest cannabinoids to be structurally characterized. Its low natural abundance in most cannabis cultivars left it largely unstudied for decades until high-CBG cultivar breeding, yeast fermentation biosynthesis,[5] and legal reforms accelerated research after 2010. As of 2026, fourteen clinical trials are registered and one published randomized controlled trial has reported results.[6]
Subjective effects include anxiety reduction, stress relief, and mild verbal memory enhancement.[6] The experience is defined by what it lacks — no intoxication, no perceptual alteration, no euphoria or impairment — a physiological modulation so subtle that subjects cannot reliably distinguish it from placebo. No characteristic unsought effects have been identified at tested doses.
CBG produces no known physical dependence, and no lethal dose has been established in any species. The primary safety concern is a hepatotoxic signal observed in rats at chronic low doses,[7] though in vitro human hepatocyte data ranked CBG as the least hepatotoxic among tested cannabinoids.[8] The compound's safety profile remains fundamentally incomplete — better understood therapeutically than toxicologically, with no published human pharmacokinetic or controlled toxicity data.
History[edit]
Discovery
Cannabigerol was first isolated from hashish in 1964 by Yehiel Gaoni and Raphael Mechoulam at the Weizmann Institute of Science in Israel.[9][10] It was among the earliest cannabinoids purified from Cannabis sativa, and its structural characterization laid groundwork for the identification of THC and CBD in the same laboratory. Despite this early discovery, CBG remained largely unstudied for decades — its carboxylated precursor, CBGA, is rapidly converted to other cannabinoid acids during plant growth, leaving most cultivars with less than 1% CBG by dry weight.[11]
Biosynthetic Significance
CBGA occupies a singular position in cannabis biochemistry: it is the universal precursor from which all major phytocannabinoid classes derive.[11][10] Three dedicated enzymes convert CBGA into the acid forms of THC, CBD, and CBC, meaning CBG accumulates only in cultivars that lack functional versions of these downstream enzymes.[12] This precursor role earned CBG the widely cited designation "the mother of cannabinoids."
Modern Emergence
Research and commercial interest in CBG accelerated after 2010, driven by the breeding of high-CBG cannabis cultivars, yeast fermentation methods enabling agricultural-independent production,[5] and legal reforms including the 2018 U.S. Farm Bill, which legalized hemp-derived cannabinoids containing ≤0.3% Δ9-THC. By 2026, CBG had transitioned from an obscure phytochemical to one of the most marketed minor cannabinoids, with fourteen registered clinical trials and the first published human RCT appearing in 2024 — more than sixty years after the compound's initial isolation.[6]
The name cannabigerol derives from Cannabis (the plant genus) and geranyl (referencing the geranyl pyrophosphate terpenoid moiety central to its structure), with the -ol suffix indicating a phenolic hydroxyl group. The designation "mother of cannabinoids" — a phrase now ubiquitous in both scientific literature and marketing — reflects CBGA's role as the metabolic starting point for THC, CBD, and CBC biosynthesis.
Chemistry[edit]
Structural Class
CBG belongs to the terpenophenol structural class. Its molecular scaffold consists of an olivetol (resorcinol) aromatic ring bearing a linear geranyl side chain — a trans-configured ten-carbon terpene unit. Unlike THC and CBD, CBG retains an open, non-cyclized geranyl moiety, representing the earliest structural stage in phytocannabinoid biosynthesis.
The structural relationship between CBG and downstream cannabinoids is one of ring closure: enzymatic cyclization of the geranyl chain produces the pyran ring of THC, the cyclohexene of CBD, or the cyclopropane bridge of CBC. CBG's retention of the linear chain defines its distinct pharmacological profile — the open terpene moiety modulates lipid membrane interactions relevant to both antibacterial activity[13] and hepatic redox effects.[7]
Molecular Properties
| Molecular formula | C₂₁H₃₂O₂ |
| Molecular weight | 316.5 g/mol |
The molecule carries two phenolic hydroxyl groups on the resorcinol ring, which are critical for receptor interactions at TRP channels and cannabinoid receptors. A five-carbon pentyl chain extends from the opposite end of the ring.
Stereochemistry
CBG does not possess chirality centers. Its geometry is defined solely by the (2E)-configured double bond in the geranyl moiety, which adopts the trans configuration. This contrasts with THC and CBD, both of which contain chiral centers created during enzymatic ring closure. The absence of chirality simplifies analytical identification and eliminates enantioselectivity considerations.
Natural Occurrence and Production
In most Cannabis sativa cultivars, CBG concentrations are low (<1% dry weight) because its precursor CBGA is rapidly converted to downstream cannabinoid acids during plant maturation.[11] Specialized cultivars homozygous for the B₀ allele — encoding non-functional cannabinoid synthases — accumulate CBG at concentrations exceeding 10% dry weight.[12]
Yeast fermentation using engineered Saccharomyces cerevisiae provides an alternative production route independent of agricultural cultivation.[5] CBG is susceptible to oxidation and thermal degradation. The geranyl chain can undergo auto-oxidation to quinone derivatives — a reaction deliberately exploited to produce the pharmacologically active PPAR-γ agonists VCE-003 and VCE-003.2.
Pharmacology[edit]
Mechanism of Action
CBG is a pleiotropic, multi-target phytocannabinoid whose pharmacological activity extends well beyond the classical cannabinoid receptors. Unlike THC, which produces psychoactive effects through potent CB1 activation, CBG operates through a distributed network of lower-affinity interactions across TRP channels, serotonin receptors, adrenoceptors, and endocannabinoid modulatory targets.
Cannabinoid Receptors
CBG functions as a weak partial agonist at both CB1 and CB2 receptors, with binding affinity estimated at 10–100 times lower than THC.[1] Functional assays confirm partial agonist activity, and animal studies demonstrate effects consistent with low-level CB1 activation — including mild pain suppression, anxiolysis, and reduced locomotion.[2] CBG also shows activity at CB1/CB2 receptor complexes.[14]
The low CB1 efficacy is the structural basis for CBG's non-intoxicating character: without the pyran ring closure that gives THC its high-affinity CB1 binding geometry, CBG cannot produce a "high."
TRP Channels
CBG's strongest receptor-level interactions occur at transient receptor potential (TRP) channels. It activates and subsequently desensitizes TRPV1 and TRPV2 channels, while acting as one of the most potent TRPM8 antagonists among cannabinoids tested.[3] TRPV1 desensitization contributes to pain relief and anti-inflammatory signaling; TRPM8 blockade has implications for cold-related pain and prostate cancer cell survival.
TRPA1 has been identified as a principal target in joint tissue, where its activation mediates calcium signaling and downstream anti-inflammatory effects.[15]
Serotonin and Adrenergic Receptors
Computational modeling predicts that CBG binds the 5-HT₁A serotonin receptor as a partial agonist,[4] consistent with the anxiolytic effects observed in human and animal studies, though this has not been confirmed by direct binding assays. Alpha-2 adrenergic receptor activity has been reported across multiple sources,[15][16] though binding affinity data remain unpublished.safety citation needed
Endocannabinoid Modulation
CBG inhibits anandamide cellular uptake comparably to CBD and inhibits the enzyme NAAA, elevating levels of endogenous anti-inflammatory lipid mediators including palmitoylethanolamide and oleoylethanolamide.[3] Unlike CBD, CBG does not significantly inhibit FAAH or MAGL. In skin cells, CBG increases CB1/CB2 receptor expression and modulates endocannabinoid enzyme activity.[17]
Pharmacokinetics
No published human pharmacokinetic studies exist for CBG. Peak concentration, half-life, oral bioavailability, and protein binding in humans are entirely unknown.safety citation needed The only species-level data come from an equine study,[18] which cannot be reliably extrapolated to humans.
As a highly lipophilic cannabinoid, CBG is expected to undergo significant first-pass liver metabolism after oral administration, predicting low oral bioavailability without formulation optimization. Chronic oral exposure in rats confirmed that CBG distributes to liver, brain, muscle, heart, kidney, and skin at low concentrations,[7] confirming central nervous system penetration.
No CBG-specific CYP450 enzyme inhibition or induction studies have been published.safety citation needed The specific liver enzymes responsible for CBG metabolism in humans are unknown, creating a direct gap in drug interaction assessment.
Neuroscience[edit]
Where It Acts
CBG modulates brain function indirectly rather than through the classical CB1-driven retrograde signaling that defines THC's central effects. By inhibiting anandamide reuptake, CBG elevates endocannabinoid tone at synapses,[3] modulating inhibitory and excitatory transmission in circuits governing mood, anxiety, and pain. This indirect mechanism — enhancing the brain's own cannabinoid signaling rather than overwhelming it — likely explains CBG's subtle, sub-perceptual experiential profile.
CBG also acts on neuroinflammatory pathways. In animal models of multiple sclerosis, Huntington's disease, and stroke, CBG reduced microglial inflammatory markers and protected neurons in a dose-dependent manner.[19][20][21] At high concentrations in cell culture, however, CBG reverses from neuroprotective to neurotoxic, dramatically increasing inflammatory markers in microglia.[22]
Why It Matters
The single published human trial found that 20 mg oral CBG enhanced verbal memory[6] — an unexpected finding for a cannabinoid, given that THC reliably impairs memory. This pro-mnemonic effect may reflect anandamide modulation at concentrations below the threshold for CB1 activation, fine-tuning hippocampal circuits rather than disrupting them.
CBG's multi-target profile — spanning TRP channels, serotonin receptors, adrenoceptors, and endocannabinoid enzymes — exemplifies the polypharmacology model, where therapeutic effects emerge from distributed, modest interactions across multiple targets rather than potent engagement of one. This predicts moderate, broadly distributed clinical effects difficult to attribute to any single mechanism.
No brain imaging studies have measured CBG's receptor occupancy at any dose, making it impossible to determine which molecular targets drive clinical effects. Whether CBG produces neuroplastic changes — as THC and psilocybin do through distinct mechanisms — has not been investigated.
Subjective Effects[edit]
CBG's experiential character is defined by its near-invisibility. At the single dose tested in humans (20 mg oral), it reduces anxiety and stress without producing intoxication, perceptual alteration, euphoria, or cognitive impairment — effects so subtle that subjects cannot reliably distinguish active drug from placebo on standard subjective measures.[6] Set and setting modulate psychological context but exert far less influence than with psychoactive cannabinoids, given the complete absence of altered consciousness.
Within the cannabinoid class, CBG occupies a position analogous to CBD but with a distinct pharmacological signature — weaker endocannabinoid enzyme inhibition, stronger cold-receptor blockade, and an unusual pro-mnemonic effect not reported for CBD. Compared to THC, CBG is experientially inert: no "high," no perceptual shift, no impairment. It functions as a physiological modulator rather than a psychoactive substance in any conventional sense.
Effect Grid
At 20 mg oral — the only dose tested in a human randomized controlled trial — CBG produces measurable anxiety suppression and stress reduction without any detectable subjective drug effects. Verbal memory is mildly enhanced relative to placebo. There is no intoxication, no altered consciousness, no euphoria or cognitive impairment. Users cannot reliably distinguish CBG from placebo on standard drug-effect scales.
Physically, no body high, sedation, motor control impairment, or somatic effects were detected at this dose. CBG is sub-perceptual in the conventional psychoactive sense — its effects register on validated anxiety and cognition instruments but not on subjective experience measures.
The 20 mg dose point comes from a single crossover trial (n=34, Cuttler 2024). No dose-response relationship has been established in humans.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Nausea suppression · Sedation
Timeline
Sub-perceptual absorption phase. CBG does not produce detectable first alerts — onset is defined pharmacologically rather than experientially. As a lipophilic cannabinoid, oral absorption begins within 30-90 minutes.
Maximum pharmacological activity. Anxiety suppression and mild memory enhancement are measurable on validated instruments but remain sub-perceptual — users cannot distinguish active drug from placebo on subjective scales.
Gradual return to baseline. No comedown effects, rebound anxiety, or residual impairment reported at 20 mg oral. CBG does not impair motor function or cognition at tested doses.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Acute Toxicity
No lethal dose data for CBG have been published in any species.safety citation needed No case reports of acute CBG toxicity or overdose in humans were identified. The single human RCT (20 mg oral, n = 34) reported no adverse events.[6] A topical safety study (0.1% CBG serum, n = 20, two weeks) also reported no adverse events.[5]
Chronic Liver Toxicity
The most concerning toxicological signal comes from a 90-day rat study. Orally administered CBG at doses as low as 0.66 mg/kg/day produced liver damage including tissue changes, disrupted blood cell counts, altered liver enzyme activity, and markers of oxidative stress.[7] The open geranyl chain in CBG's structure was proposed as the chemical feature responsible for this oxidative disruption.[7]
Liver toxicity signals were observed at very low doses (0.66 mg/kg/day) in a 90-day chronic exposure model. Human relevance has not been established, but these findings warrant caution regarding long-term CBG use, particularly in individuals with pre-existing liver conditions.
A contrasting result emerged from human cell-derived liver models: CBG ranked as the least hepatotoxic among tested cannabinoids, with CBN, CBD, and CBC all showing greater liver toxicity potential.[8] The apparent discrepancy may reflect differences between short-term cell exposure and 90-day whole-animal exposure, or species-specific metabolic differences. Neither finding alone is sufficient to characterize CBG's liver safety.
Cell Toxicity at High Concentrations
At high concentrations in laboratory studies, CBG was highly toxic to microglial brain cells, dramatically increasing inflammatory markers and reactive oxygen species.[22] DNA damage was detected at moderate-to-high concentrations in one assay but not another.[22] Cell toxicity was also observed in neuronal cell cultures.[23]
These laboratory concentrations are substantially higher than those expected at therapeutic doses, but the concentration-dependent toxicity profile underscores the importance of dose selection.
Psychological Risks
No psychological adverse effects have been reported in human studies. The single RCT found that 20 mg oral CBG produced no subjective drug effects, intoxication, or altered consciousness.[6] CBG does not produce the anxiety, paranoia, or psychotic symptoms that can occur with THC.
The absence of CB1-mediated psychoactivity at tested doses predicts minimal risk for acute psychological distress. No data exist on psychological effects at higher doses, and chronic psychological effects have not been studied.
Tolerance and Dependence
No studies have characterized CBG tolerance, dependence, or withdrawal in any species.safety citation needed
Cannabis tolerance and dependence are primarily driven by CB1 receptor changes following sustained THC exposure. CBG's weak CB1 activity is insufficient to produce this receptor adaptation. The human RCT found no reinforcing or psychoactive effects at 20 mg oral,[6] suggesting low abuse potential, but formal abuse liability testing has not been conducted.
Cross-tolerance between CBG and THC has not been studied but is considered unlikely given CBG's low CB1 efficacy.
Drug Interactions
No published drug interaction studies for CBG exist.safety citation needed
CBG is presumably metabolized by liver CYP enzymes, but its specific enzyme profile is unknown. Interaction with drugs metabolized by CYP3A4 or CYP2C9 is theoretically possible based on analogy with other cannabinoids but has not been documented. Until enzyme interaction data are available, co-administration with drugs that have a narrow safety margin warrants caution.
CBG demonstrates synergistic pain-relieving interactions with other non-intoxicating cannabinoids (CBD, CBC, CBDV) through calcium channel mechanisms.[24] Commercial CBG products frequently contain trace amounts of other cannabinoids and plant compounds that may contribute to drug interactions independently of CBG itself.
Contraindications
No contraindication data specific to CBG have been published.safety citation needed The following are inferred from available evidence:
- Liver conditions: The rat study demonstrating liver toxicity at 0.66 mg/kg/day[7] warrants caution in individuals with pre-existing liver disease, elevated liver enzymes, or concurrent use of liver-toxic medications.
- CYP-metabolized medications: Patients taking medications metabolized by CYP3A4, CYP2C9, or CYP2C19 should exercise caution, as cannabinoid-class enzyme inhibition is plausible but uncharacterized for CBG.safety citation needed
- Pregnancy and breastfeeding: No reproductive or developmental toxicity data exist. Use during pregnancy or lactation cannot be recommended.
- Children and adolescents: No safety data exist for minors.
Harm Reduction[edit]
Forms & Identification
CBG is primarily available as oral tinctures, capsules, and oils derived from high-CBG hemp cultivars or isolated through extraction. Full-spectrum products contain trace amounts of other cannabinoids and terpenes; isolate products contain CBG alone.
The critical identification concern is not CBG substitution — the compound has no recreational value that would incentivize counterfeiting — but rather undisclosed THC content in products labeled as hemp-derived. Third-party certificates of analysis from accredited laboratories are the only reliable method for verifying cannabinoid content, THC levels, and the absence of contaminants such as heavy metals, pesticides, and residual solvents.
Guidelines
- Start with a low dose and increase gradually. The only controlled human data exist at 20 mg oral — effects at higher doses are uncharacterized.
- Use products with current, third-party certificates of analysis confirming cannabinoid content and THC levels below legal thresholds.
- If using CBG for a specific purpose (anxiety, sleep, pain), keep a brief written log of dose, timing, and perceived effects to evaluate personal response over time.
- Avoid long-term daily use until more chronic safety data are available, given the hepatotoxic signals observed in animal studies.
- If taking prescription medications, consult a healthcare provider — CBG's drug interaction profile is entirely uncharacterized.
Set & Setting
CBG does not produce intoxication or altered consciousness at tested doses, making set and setting less critical than with psychoactive cannabinoids. Users exploring CBG for anxiety or stress reduction should still note baseline mood and any concurrent medication use.
Because CBG's effects are subtle and often sub-perceptual, establishing a consistent routine and environment helps in evaluating whether the compound produces a noticeable personal response.
Aftercare & integration. CBG does not produce altered states of consciousness requiring integration in the psychedelic sense. For users taking CBG for anxiety or stress management, periodic reassessment is more useful than post-session processing.
Evaluate whether sustained use is producing the intended benefit, note any changes in sleep, appetite, or mood over weeks rather than hours, and adjust dosing or discontinue if no benefit is apparent. If using CBG as part of a multi-cannabinoid regimen, track which components are contributing to the overall effect.
Recovery & Support
No dependence syndrome or withdrawal pattern has been documented for CBG. If CBG use has become part of a broader pattern of cannabinoid or supplement dependence — using multiple products compulsively or escalating doses without clear benefit — general substance use support resources may be helpful.
SAMHSA's National Helpline (1-800-662-4357) provides free referrals. For individuals using CBG alongside THC products where THC dependence is a concern, cannabis-specific support communities and counseling services can address the broader pattern.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
CBG emergencies are unlikely given the compound's non-intoxicating profile, but adverse reactions to contaminated or mislabeled products are possible.
Recognizing an emergency: Severe allergic reaction (difficulty breathing, facial swelling, hives), signs of liver distress with chronic use (yellowing of skin or eyes, severe abdominal pain, dark urine), or any reaction inconsistent with a non-psychoactive cannabinoid — which may indicate product contamination or mislabeling.
Immediate steps:
- 1. Stop taking the product immediately.
- 2. If breathing difficulty or swelling occurs, call emergency services.
- 3. Retain the product and its packaging for identification.
- 4. If symptoms suggest THC intoxication (anxiety, rapid heartbeat, disorientation), move to a calm, safe environment and wait — effects will resolve.
What to tell the dispatcher: Name the substance (cannabigerol/CBG), the amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help.
Legal Status[edit]
CBG's legal status is determined by its botanical origin and the regulatory framework governing cannabinoids in each jurisdiction. No country or international body has enacted scheduling or restrictions targeting CBG specifically; its classification derives entirely from broader hemp and cannabis laws.[25]
In jurisdictions where hemp-derived cannabinoids are legal, CBG occupies a permissive regulatory space. Where all cannabis-derived compounds are controlled, CBG's legality depends on the source plant's THC content.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Legal (hemp-derived) | Federally legal under the 2018 Farm Bill when derived from hemp containing ≤0.3% Δ9-THC dry weight. Not scheduled. State-level regulations vary[25] |
| United Kingdom | Legal (hemp-derived) | Legal from EU-approved industrial hemp strains with <0.2% THC. Products must not make unapproved medical claims[25] |
| European Union | Legal (hemp-derived) | Legal from EU-approved hemp strains with <0.2% THC. Member states may impose additional restrictions[25] |
| Canada | Regulated (Cannabis Act) | Regulated under the Cannabis Act. Legal when compliant with Cannabis Regulations[25] |
| Australia | Legal (hemp-derived) | Legal from hemp with <0.3% THC under TGA regulations. Cannabis-derived CBG may be controlled[25] |
CBG is not detectable by standard drug tests designed for THC metabolites. However, commercial CBG products may contain trace THC, which could produce positive results on immunoassay screens. Third-party certificates of analysis from accredited laboratories are the primary method for verifying cannabinoid content and purity.
The legal landscape for hemp-derived cannabinoids remains dynamic. The 2018 Farm Bill is subject to reauthorization, and individual U.S. states continue to enact legislation restricting specific hemp-derived cannabinoids. Consumers and researchers should verify current jurisdiction-specific regulations before obtaining or studying CBG products.
references
- [1] ^abQueiroz CM, de Oliveira Koren L, da Silva CRP, Ribeiro S, Silva SRB (2025) Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. — Progress in Brain Research doi:10.1016/bs.pbr.2025.07.006
- [2] ^abZagzoog A, Mohamed KA, Kim HJJ, et al. (2020) In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa — Scientific Reports doi:10.1038/s41598-020-77175-y
- [3] ^abcdDe Petrocellis L, Ligresti A, Moriello AS, et al. (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes — British Journal of Pharmacology doi:10.1111/j.1476-5381.2010.01166.x
- [4] ^abYap BK, Palmer S, Piccariello T (2026) In silico insights on the binding site and function of cannabinoids and cannabinoid acids on human 5-HT1A receptor — Journal of Molecular Graphics and Modelling doi:10.1016/j.jmgm.2025.109186
- [5] ^abcdPerez E, Fernandez JR, Fitzgerald C, Rouzard K, Tamura M, Savile C (2022) In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis — Molecules doi:10.3390/molecules27020491
- [6]